Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.45 |
| ▸ | CHRNG | P07510 | 2/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.45 |
| ▸ | CHRND | Q07001 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 4/20 | 0.43 |
| ▸ | NMT2 | O60551 | 3/20 | 0.43 |
| ▸ | NMT1 | P30419 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576026 | 0.95 | NMT1 (0.46) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL20272636 | 0.95 | NMT1 (0.46) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL18359086 | 0.94 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL20706554 | 0.94 | NMT1 (0.48) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL14642615 | 0.92 | GNAI3 (0.44) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL14616413 | 0.91 | GNAI3 (0.59) | GNAI3GNAO1GNAI1CHRNA1CHRNG | |
| SCHEMBL14707968 | 0.90 | NMT1 (0.47) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL15084741 | 0.89 | NMT1 (0.42) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL21233587 | 0.87 | NMT1 (0.43) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL14616462 | 0.87 | GNAI3 (0.59) | GNAI3GNAO1GNAI1CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | GNAI3 3017/4885GNAO1 3483/4885GNAI1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.